Coricidin D

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Coricidin D

Quick Facts

Property Description
Active Ingredients Seven-component blend (Acetaminophen, Aspirin, Caffeine, Chlorphenamine Maleate, Phenylephrine HCl, Phenylpropanolamine)
Form Oral Tablet or Caplet
Pharmacological Class Fixed-Dose Combination of Analgesic, Antihistamine, Decongestant, and CNS Stimulant
Common Use Multi-symptom relief for cold and flu discomforts
Origin Synthetic

What Type of Medicine is Coricidin D?

Coricidin D is a synthetic, fixed-dose combination product designed for systemic use, typically presented as an oral tablet or caplet and historically marketed as an Over-the-Counter (OTC) preparation. It is classified as a multi-component medicine that intentionally blends four distinct pharmacological classes to achieve broad symptomatic coverage. This category is distinct from single-ingredient drugs, delivering simultaneous therapeutic actions against various discomforts. Combination analgesics are used in over-the-counter products to enhance the pain-relieving effect of the individual components. The specific design, featuring multiple active agents in one preparation, makes it a targeted solution for individuals seeking comprehensive, rather than isolated, relief.

Comprehensive Composition and Active Ingredients

The preparation's identity is defined by its extensive seven-component composition. Its active blend includes the recognized International Nonproprietary Names (INN) Acetaminophen, Aspirin, Caffeine, Chlorphenamine Maleate (or Chlorpheniramine), Phenylephrine Hydrochloride, and Phenylpropanolamine. These ingredients fulfill specific roles: Acetaminophen and Aspirin are included for their analgesic and antipyretic effects, while Chlorphenamine Maleate acts as an antihistamine. Phenylephrine acts as a nasal decongestant due to its ability to restrict blood vessels. The inclusion of Caffeine acts as a CNS stimulant, a formulation choice intended to counter the sedative effects often associated with the antihistamine component.

General Purpose and Multi-Symptom Relief

The general purpose of Coricidin D is to provide multi-symptom relief for the temporary discomforts of the common cold and flu. The rationale for its complex formulation is the integrated approach it offers: it addresses generalized issues like body aches and fever concurrently with local respiratory symptoms such as nasal congestion and excessive secretions. This design allows the medication to offer overall symptomatic management across diverse physiological systems, which defines the primary benefit of a comprehensive fixed-dose combination.

Regulatory References

  1. NIH Phenylephrine Efficacy

What side effects are possible with Coricidin D?

Possible Side Effects and Safety Information

The official safety profile for this fixed-dose combination product is characterized by adverse reactions associated with its six active components, categorized by official regulatory bodies into specific System-Organ Classes (SOCs).

Commonly Documented Adverse Reactions

Adverse reactions classified as Very Common or Common in regulatory documents largely relate to the Central Nervous System (CNS) and include drowsiness (somnolence), dizziness, and headache. Other common effects include anticholinergic manifestations such as dry mouth and blurred vision [Source 1.1, 4.2].

Serious Adverse Reactions

The safety labeling documents the potential for rare but clinically significant adverse reactions. The Acetaminophen component is associated with the risk of severe liver damage (hepatotoxicity), which can be fatal. The Phenylpropanolamine (PPA) component is linked to an association with an increased risk of hemorrhagic stroke, an observation that prompted a formal public health recommendation by the U.S. Food and Drug Administration (FDA) to avoid PPA-containing products [Source 2.3, 3.1]. Furthermore, severe allergic reactions and gastrointestinal bleeding (linked to Aspirin, if included) are officially noted risks [Source 1.4, 5.1].

Safety Constraints and Specific Populations

Official regulatory documents emphasize specific safety constraints. Caution is required in patients with pre-existing conditions such as hypertension, heart disease, glaucoma, or diabetes. Patients taking monoamine oxidase inhibitors (MAOIs) are strictly constrained from using this medicine due to documented interaction risks [Source 1.2, 5.1]. Older adults are noted in labeling as having a higher risk for CNS effects like confusion and dizziness, and children may experience the paradoxical effect of hyperactivity or excitation [Source 1.1, 4.2].

This information structures the understanding of the medicine’s risk profile, focusing on officially documented events and high-risk scenarios defined by governmental health authorities.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of this multi-component product involves the combined toxicity of its active ingredients, requiring immediate emergency medical care. The official regulatory labeling mandates that individuals seek immediate medical attention or call a Poison Help line right away for any suspected overdose, even if initial symptoms are absent. This urgency addresses the potential for delayed severe organ toxicity.

Documented Manifestations and Severe Outcomes

Early documented signs of overdose often include non-specific symptoms such as nausea, vomiting, abdominal pain, and paleness. However, severe manifestations from the combined components can progress to neurological effects (confusion, tremor, excitability), cardiovascular issues (irregular heartbeat, increased blood pressure), and metabolic disturbances.

The most serious outcomes described in regulatory documents are related to the analgesic components: severe liver damage progressing to liver failure from Acetaminophen and metabolic acidosis leading to multi-organ failure from Aspirin (salicylates). In children and teenagers, the aspirin component is formally associated with the risk of Reye Syndrome.

Required Emergency Management

Emergency management, as described in official documents, is primarily supportive. For the Acetaminophen component, a specific antidote medicine is available for administration. Procedures such as activated charcoal to limit absorption or hemodialysis to enhance drug removal for severe salicylate poisoning may be required in the hospital setting. Continuous hospital monitoring is necessary to track drug levels, liver function, and metabolic status.

Therapeutic Uses of Coricidin D

Coricidin D is commonly used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is needed for the common cold and influenza. It is generally applied in settings where symptoms may intensify temporarily, often used when supportive relief is needed. Combination products are relevant for managing conditions characterized by periods of heightened symptoms.

The medication is commonly used to help manage the symptom cluster that includes minor aches, headache, elevated body temperature (fever), a stuffy nose (nasal and sinus congestion), and secretory symptoms such as runny nose and sneezing. This use contributes to improved day-to-day comfort and supports general well-being during symptomatic phases.

“This application is relevant for symptoms that create noticeable physiological strain and are linked to organ-specific functional stress.”

Quick Fact: Relief for Multi-Symptom Cold Clusters Therapeutic Focus Primary Benefit
Systemic Discomfort Contributes to easing the overall symptom load and is relevant for managing symptoms related to inflammatory or irritative states.
Nasal Function Helps improve day-to-day comfort during symptomatic periods and is relevant for easing symptoms related to heightened physiological activity.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Coricidin D

The eligibility for using Coricidin D is governed by explicit regulatory rules regarding age, pre-existing health conditions, and concurrent medication use. This medication is approved for use by adults and children 12 years and over.


Classification Population Status
Absolute Contraindication Individuals taking a Monoamine Oxidase Inhibitor (MAOI), or within 2 weeks of stopping one. Do Not Use
Individuals with a known allergy to any product ingredient. Do Not Use
Age Restriction Children under 12 years of age. Prohibited
Conditional Use Patients with liver disease, glaucoma, or trouble urinating due to an enlarged prostate gland. Consult a Doctor
Reproductive Status Individuals who are pregnant or breast-feeding. Consult a Professional

Official Eligibility Statements:

Regulatory labeling establishes that patients must not use Coricidin D if they are currently taking an MAOI or have a history of hypersensitivity to the ingredients. Ask a doctor before use is mandatory for individuals with chronic conditions such as liver disease or an enlarged prostate, and also for those who are pregnant or breastfeeding. These rules strictly define the non-eligible and conditionally eligible patient populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Coricidin D details significant drug–drug and drug–substance interaction risks arising from its multi-component formulation.

Contraindicated and Restricted Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated due to the potential for severe adverse reactions, such as hypertensive crisis, related to the sympathomimetic components (Phenylephrine and Phenylpropanolamine). A mandatory 14-day separation period is required after discontinuing MAOI therapy before this medication may be administered. Furthermore, taking Coricidin D with any other acetaminophen-containing product is formally restricted to prevent reaching toxic cumulative doses, which may lead to severe liver damage.

Pharmacodynamic and Exposure Interactions

The presence of Chlorphenamine Maleate (an antihistamine) necessitates restrictions on co-use with other Central Nervous System (CNS) depressants, including alcohol, due to the documented risk of additive CNS depression. The Acetaminophen component is officially known to potentiate the effect of Warfarin (and other Vitamin K Antagonists), increasing the risk of bleeding. Regulatory documents also note that combining the Aspirin component with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen, increases the risk of gastrointestinal bleeding and ulcers. The decongestant components also carry a risk of additive cardiovascular effects when co-administered with other sympathomimetics.

Mechanism of Action

How Coricidin D Works

Coricidin D's effect profile is achieved through the concurrent action of its active ingredients across four major pharmacodynamic domains.


️ Modulating Central Pain and Thermoregulatory Pathways

This mechanism involves the inhibition of Cyclooxygenase (COX) enzymes by Acetaminophen and Aspirin, primarily leading to the reduced synthesis of Prostaglandin E2 (PGE(2)) in the central nervous system ( CNS). By dampening PGE2 signaling in the hypothalamus, the mechanism alters the body’s core temperature set-point and modulates nociceptive signaling within the CNS.


Regulating Vascular Tone via Adrenergic Activation

The decongestant components (Phenylephrine and Phenylpropanolamine) act as sympathomimetics by targeting Alpha-1 (alpha1) Adrenergic Receptors on vascular smooth muscle. This alpha1 agonism initiates a cascade of smooth muscle contraction, resulting in the constriction of engorged blood vessels in the respiratory mucosa and a resulting decrease in local blood volume.


Antagonizing Histamine and Adenosine Systems

Chlorphenamine blocks Histamine H1 receptors, preventing Histamine from binding to these sites, which reduces capillary permeability and fluid exudation. Concurrently, Caffeine's action as an Adenosine receptor antagonist blocks the inhibitory effects of endogenous Adenosine, resulting in increased neuronal excitability and functional antagonism of the Chlorphenamine-induced central inhibition.

Dosage and Administration Information

Coricidin D is a fixed-dose combination medicine whose administration protocol is strictly defined by regulatory guidelines, focusing on specific dosing, frequency, and duration limits. The guidelines are derived from official labeling for the tablet containing Acetaminophen 325 mg and Chlorpheniramine maleate 2 mg per unit.


Standardized Usage Protocol

The medicine is administered via the oral route as an intact tablet, following a frequency pattern of as-needed (intermittent use) with a precise interval of every 4 to 6 hours. This regimen governs the use of the product, which is classified as an oral combination formulation.

Labeled Dosing Regimens

Age Group Single Dose Maximum Tablets in 24 Hours
Adults and Children 12+ 2 tablets 12 tablets
Children 6 to under 12 1 tablet 5 tablets
Children under 6 Ask a doctor Ask a doctor

Administration Constraints and Duration

The official instructions establish a critical constraint against co-administration: the product must not be used with any other medication containing acetaminophen to prevent the accidental exceeding of the daily maximum limits. The protocol also defines a maximum duration for use, requiring administration to be discontinued if pain lasts more than 10 days or if fever persists for more than 3 days. These regulatory boundaries define the short-term, standardized protocol for using the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Coricidin D

Evidence for Multi-Symptom Relief of the Common Cold

Research into multi-component products, such as those combining an analgesic/antipyretic, an antihistamine, and a decongestant, primarily relies on Randomized Controlled Trials (RCTs). These are studies used in research exploring how symptoms change over time by comparing the fixed-dose combination against an inactive substance (placebo) or against a single active ingredient. The research examined outcomes related to physical discomfort.

Studies monitored changes over defined time intervals and primarily focused on patient-reported outcomes describing perceived discomfort. Outcomes related to systemic or functional imbalance were evaluated, including a standardized Total Symptom Score (TSS) and assessments of changes in individual symptoms such as headache, fever, stuffy nose (nasal congestion), and runny nose. Research highlights changes measured during the study period, with research describing patterns observed in populations administered the combination product versus those administered a placebo. Research highlights that the observed patterns applied to short-term periods, which aligns with the acute duration of the common cold. The existing research describes group patterns, not personal outcomes.


Study Design, Follow-Up Periods, and Evidence Scope

The studies conducted during periods of increased symptom activity generally focused on short-term symptom changes over periods lasting only 2 to 5 days, which captures the most disruptive phase of the cold. The research explored short-term symptom changes, and the follow-up durations were limited to the duration of the acute episode.

The evidence level assigned in systematic reviews for these combinations is generally considered Moderate. This classification acknowledges that evidence is derived from multiple clinical trials and meta-analyses, and that findings were mixed regarding the consistency of the short-term changes monitored. Evidence quality varies across studies, and findings help contextualize how patients reported their experience during temporary physiological imbalance.


Research Gaps and Areas of Uncertainty

There is limited information for long-term outcomes associated with repeated or extended use of the combination, meaning long-term effects are not fully established. The populations studied were primarily healthy adults, and data for certain groups remain insufficient, meaning there is limited information available for older adults or pediatric groups.

An area of uncertainty relates to the specific ingredients. Studies monitored the oral decongestant component (Phenylephrine), and research describes mixed findings, which contributes to ongoing discussion regarding its role in the fixed-dose combination. Furthermore, systematic reviews often include similar but not identical multi-component formulations; this means data for every exact combination may be insufficient, and comparative evidence remains limited.

Key Studies & References FDA Nonprescription Drugs Advisory Committee Oral Phenylephrine Meeting Summary (2023)

Frequently Asked Questions (FAQ)

Common questions about Coricidin D (FAQ)

Q: What is the main difference between Coricidin D and other non-D Coricidin products?

The fundamental difference is that Coricidin D formulations are designed to contain ingredients classified as nasal decongestants. In contrast, other products in the Coricidin line, such as those labeled 'HBP' (High Blood Pressure), are specifically formulated without these decongestant components.

Q: Does Coricidin D contain pseudoephedrine as an active ingredient?

The inclusion of pseudoephedrine is dependent on the specific product formulation and the location where it is sold. Historically, some 'Coricidin D' products have contained pseudoephedrine sulfate as an active ingredient.

Q: Why is Coricidin D sometimes sold from behind the pharmacy counter?

Regulatory requirements dictate that some medications must be sold from behind the pharmacy counter for monitoring purposes. This is primarily due to the presence of certain decongestant ingredients, such as pseudoephedrine, whose sales are subject to regulatory restrictions.

Q: How long does the congestion relief from Coricidin D typically last?

The formula is designed for short-term symptom management. The effect profile of the active ingredients is generally intended to align with the recommended administration interval of every four to six hours.

Q: What is the difference in ingredient purpose between Coricidin D and Coricidin HBP?

Coricidin D is intended to relieve nasal congestion and includes a decongestant ingredient for that purpose. Coricidin HBP products are specifically designed without a decongestant, making them a formulation option for individuals who seek to avoid ingredients known to affect blood pressure.

Q: Does Coricidin D help to relieve a cough?

Official labeling and product information for many Coricidin variants indicate the inclusion of a cough suppressant. Ingredients like dextromethorphan are frequently added to help relieve a cough associated with the common cold.

Q: Is Coricidin D classified as a controlled or regulated substance in the United States?

While the product is sold over-the-counter, certain ingredients are subject to specific Federal and State regulations. Due to the presence of these components, the medicine's sale may be subject to quantity limits and mandatory record-keeping.

Q: Are changes in mood a potential side effect described in official documents for Coricidin D?

Official regulatory texts describe that serious side effects can, in rare cases, include effects on mental status. These potential mental or mood changes may include confusion or the occurrence of hallucinations.

Q: What is the guidance regarding Coricidin D use and driving or operating machinery?

The official label contains a clear warning to exercise caution when operating heavy machinery or driving a motor vehicle. This guidance is provided because common side effects like drowsiness or dizziness may occur while using the medicine.

Q: Why do people sometimes refer to Coricidin D as 'Sudafed-containing Coricidin'?

People often refer to Coricidin D in this way because the term 'Sudafed' is a widely recognized brand name for the decongestant pseudoephedrine. Since Coricidin D contains or once contained this type of decongestant, the association is common in public discourse.

Q: Does Coricidin D contain any ingredients that might cause a false positive on a drug screening test?

Health information notes that certain ingredients in the product, such as dextromethorphan and chlorpheniramine, can interfere with laboratory tests. The presence of these ingredients may cause interference that leads to a non-negative result during the initial drug screening.

Q: Can Coricidin D potentially cause difficulty sleeping or insomnia?

Official product information states that drowsiness may occur as a side effect. However, the label also warns that excitability may occur in some individuals, particularly children, which could potentially interfere with normal sleep patterns.

Q: Is a feeling of restlessness or 'jitters' associated with using Coricidin D?

According to official labels, the product has the potential to cause restlessness or a feeling of being 'excited.' This is listed as a possible side effect that may occur while using the medicine.

Q: Can older adults or seniors use Coricidin D according to official guidance?

Official regulatory warnings indicate that older adults may have a greater risk for certain side effects. These risks include central nervous system effects such as confusion or dizziness.

Q: Can Coricidin D be used to manage seasonal allergy symptoms?

Regulatory documents state that the product temporarily relieves symptoms like sneezing and runny nose. Due to the presence of an antihistamine component, the product addresses symptoms such as sneezing and runny nose.

Q: What other over-the-counter medicines contain ingredients similar to Coricidin D?

Official warnings strictly advise against taking this product with any other medication containing acetaminophen. This is a critical regulatory constraint intended to prevent accidental exceeding of the maximum daily acetaminophen limit.

Q: Does Coricidin D interact with specific dietary supplements or herbal products?

Regulatory guidance advises caution regarding potential combinations. Depending on the exact formulation, some ingredients may interact with substances like grapefruit juice, which can alter how the body processes the medicine.

Q: Can using Coricidin D affect blood pressure readings?

The decongestant ingredients found in some Coricidin D formulations have the potential to elevate blood pressure. This effect is why official warnings list pre-existing hypertension and the use of blood pressure medications as conditions requiring professional consultation before use.

Q: Are there specific food items or beverages that should be avoided when using Coricidin D?

The regulatory label contains a specific warning to avoid or limit the consumption of alcohol while using the product. Combining alcohol with the medication increases the risk of additive central nervous system (CNS) depression and severe liver injury.

How should Coricidin D be stored and disposed of?

How to Store and Dispose of Coricidin D?

The official storage conditions for Coricidin D products, according to regulatory documents, require maintaining product stability within defined environmental controls.


Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Must be kept away from excessive heat and moisture. Liquid-gel capsule products require protection from freezing.
Container Keep the product in its original container, which must be kept tightly closed.
Child Safety Keep out of reach of children.

Disposal Instructions

Official disposal guidance recommends using a drug take-back program when available. If a take-back program is not accessible, the product should be disposed of in the household trash after mixing it with an unappealing substance, and the mixture must be placed in a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Coricidin D found in:

A-Z Index: